Revolution Medicines, Inc.
Biological Products, (No Diagnostic Substances)
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers.
It is a $40.7B healthcare company. It holds more cash than debt.
- Website
- revmed.com
- Location
- Redwood City, CA
- Employees
- 883
- Sector
- Healthcare
Skills
Six independent scores, 0–100, built from reported numbers and valuation history. Click a row to see how it was scored.
Strong health; Valuation, Growth, Profitability, Quality and Moat lag behind.
Valuation20
- P/E vs own historyn/a · 10/25
- FCF yield-6.5% · 0/25
- P/S3514.7x · 0/25
- EV/EBITDAn/a · 10/25
Growth0
- Revenue CAGRn/a · 0/25
- Net income CAGRn/a · 0/25
- EPS CAGR ~5Yn/a · 0/25
- Fwd implied growthn/a · 0/25
Profitability0
- ROICn/a · 0/25
- ROE-54.1% · 0/25
- Net margin-2833.9% · 0/25
- Operating margin-3145.0% · 0/25
Health75
- Altman Zn/a · 0/25
- Current ratio11.38 · 25/25
- Interest coverageno interest expense · 25/25
- Net cash / debtNet cash · 25/25
Quality0
- Piotroski F1/9 · 0/25
- Beneish Mn/a · 0/25
- FCF conversionn/a · 0/25
- Margin stabilityσ 1034.0% · 0/25
Moat0
- ROIC >12% years0/6 yrs · 0/25
- Median gross margin-670.4% · 0/25
- FCF-positive years0/7 yrs · 0/25
- Worst-year net marginworst -2348.4% · 0/25
Achievements
Verifiable track record, straight from the reported numbers.
Strengths & watch-outs
What a bull and a bear would each point to. Both lists come from the reported numbers, not opinions.
Strengths
- Net cash position after subtracting debt from cash
Watch-outs
- Not profitable — 2833.9% net margin
- Negative free cash flow (-$2.7B)
- Loss-making in 6 of the recent years
Qualifications
The basics a company should meet before you research it further. Each check uses the reported numbers.
- Revenue growing — the company sells more than a year agono data
- Profitable — makes more than it spends-$3.45B TTM
- Profit growing — earnings are higher than last year+39.7% YoY
- Generates cash — cash left after running and investing-$2.65B TTM
- Debt under control — could handle its obligationsmore cash than debt
- Established company — not a micro-cap — lower blow-up risk$40.7B market cap
- Not printing shares — share count not ballooning — you keep your slice+37.9% shares over ~5y
- Proven track record — years of profitability behind it0/7 profitable years
- Financially stable — balance sheet not near distresshealth score 50/100
- Pays a dividend — returns cash to shareholdersno data
- Valuation not extreme — price not wildly above earningsno data
Peer comparisonRevolution Medicines, Inc. vs 6 largest healthcare peers — cap, P/E, growth and margin side by sideOpen ▾Close ▴
| Company | Market cap | P/E | Revenue growth | Net margin | Profile |
|---|---|---|---|---|---|
| RVMD this company | $40.7B | — | — | — | Mixed |
| LLY Eli Lilly & Co. | $1.0T | 41.6 | +49.6% | 33.5% | Solid |
| JNJ Johnson & Johnson | $630.9B | 29.9 | +8.1% | 21.5% | Mixed |
| ABBV Abbvie Inc. | $488.5B | 77.4 | +10.4% | 9.8% | Mixed |
| MRK Merck & Co., Inc. | $361.0B | 113.2 | +4.6% | 4.8% | Mixed |
| UNH UNITEDHEALTH GROUP INCORPORATED (Delaware) | $340.7B | 24.1 | +6.5% | 3.1% | Mixed |
| NVS Novartis AG | $273.2B | 20.3 | +9.6% | 24.7% | Solid |
Head-to-head: RVMD vs LLY · RVMD vs JNJ · RVMD vs ABBV
References
What covering analysts publish about the company — information only, not a recommendation.
Appendix · Financial records
The full statements behind this CV, FY2020–FY2026. For readers who want to check the numbers.
Live data and quarterly detail: stockcv.com/RVMD
Want the live picture — intraday moves, valuation history and full analysis?
Deeper analysis of RVMD on PreMarketPriceFigures are derived from company filings (quarterly values normalised from as-filed year-to-date data where applicable) and may be delayed, restated or incomplete. This page is information, not investment advice. Latest price $189.76 · market cap $40.7B.